Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

News Center

6756758(2)-91.jpg

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development

Learn More

All

2025

2024

2023

2022

2021

2020

LaNova Medicines Announces IND Approval of LM-305 by US FDA

2022-07-30

Learn More
LaNova Medicines Announces the IND Approval of CCR8-targeting monoclonal antibody LM-108 by China NMPA

2022-06-01

Learn More
LaNova Medicines and Turning Point Therapeutics Enter Into a Licensing Agreement for LM-302

2022-05-05

Learn More
LaNova Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

LaNova Medicines will present two posters featuring preclinical data of LM-108 and LM-305 (Abstract No. 6008 & 6020) at the American Association for Cancer Research (AACR) 2022 Annual Meeting, to be held April 8-13, 2022.

2022-03-31

Learn More
LM-108 Submitted US FDA Clinical Trial Application

CCR8 antibody LM-108 submitted US FDA clinical study application in December 2021. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-108.

2021-12-23

Learn More
LaNova Medicines Launches R&D Center after Relocation

2021-11-30

Learn More

5